CLINICAL ROLE -
January 24th 2025
Biosimilar use is not linked to an increased risk of treatment failure among pediatric patients with inflammatory bowel disease (IBD).
January 20th 2025
Recommendations help influence the rate of gastric emptying, improve compliance, and prevent interruption of weight loss for patients.
January 16th 2025
This is mirikizumab’s second FDA-approved indication in inflammatory bowel disease.
January 7th 2025
The tablets are indicated for treatment of adults with chronic idiopathic constipation, with further research needed to assess efficacy and safety in children.
January 3rd 2025
Adherence to thiopurine medications after 6 months of use was 87.9% under direct pharmacist care but 65.7% under general practitioner guidance.